Income statement
USD
Annual
| Metric | 2007 | 2006 | 2005 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Income | 128K | 47K | 33K |
| EBITDA | -128K | -46K | -33K |
| Net Income | -128K | -47K | -33K |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 16, 2026
Coverage: 252 bars · Jun 20, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xeno Transplants Corporation (XENO) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +61.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +61.0%, free cash flow -1909.5% with operating margin 0.0% and ROIC 33.2%. Stock Foundry combines XENO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XENO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XENO Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XENO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$32.7K
+29.9% YoY
Free Cash Flow
-$39.3K
-42.5% YoY
Revenue Growth
+0.0%
EPS Growth
+61.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2007 | 2006 | 2005 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Income | 128K | 47K | 33K |
| EBITDA | -128K | -46K | -33K |
| Net Income | -128K | -47K | -33K |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2007 | 2006 | 2005 |
|---|---|---|---|
| Cash & Equivalents | 32K | 29 | 28K |
| Total Assets | 641K | 797 | 34K |
| Total Liabilities | 255K | 13K | 0 |
| Shareholder Equity | 386K | -13K | 34K |
| Total Debt | 0 | 0 | 0 |
| Net Debt | -32K | -29 | -28K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
39K
-48.6% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
39K
-42.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-68.6%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.